Article Impact Level: HIGH Data Quality: STRONG Summary of Clinical Cardiology, 46(6), 698–706. https://doi.org/10.1002/clc.24014 Dr. Hiroki Teragawa et al.
Points
- The research investigates the impact of febuxostat, a selective xanthine oxidase inhibitor with reported antioxidant properties, on malondialdehyde-modified low-density lipoprotein (MDA-LDL) levels in asymptomatic hyperuricemic patients with carotid atherosclerosis.
- A subanalysis of the PRIZE trial involved 383 patients, split into a febuxostat group (n = 200) and a control group (n = 183) over two years.
- The febuxostat group showed a significant reduction in the MDA-LDL/LDL-C ratio, potential oxidative stress, and atherosclerosis marker compared to the control group (p = .025).
- However, no significant differences were observed in estimated changes in MDA-LDL and LDL-C levels between the two groups.
- The study found no significant correlation between febuxostat doses and MDA-LDL, LDL-C, or MDA-LDL/LDL-C ratio changes. Further research is needed to validate and explore the clinical antioxidant effects of febuxostat.
Summary
The research paper investigates the effects of febuxostat, a selective xanthine oxidase inhibitor known for its potential antioxidant properties, on malondialdehyde-modified low-density lipoprotein (MDA-LDL), an oxidative stress marker. The study, a subanalysis of the PRIZE trial, focused on asymptomatic hyperuricemic patients with carotid atherosclerosis over two years.
The researchers recruited 383 patients from the PRIZE trial and divided them into the febuxostat group (n = 200) and the control group (n = 183). They examined MDA-LDL, low-density lipoprotein cholesterol (LDL-C), and MDA-LDL/LDL-C ratio levels by estimating the differences from baseline to 24 months. Additionally, they explored the relationship between febuxostat dose and changes in MDA-LDL level, LDL-C level, and MDA-LDL/LDL-C ratios.
The results showed that the febuxostat group exhibited a significantly lower estimated change in the MDA-LDL/LDL-C ratio compared to the control group (p = .025). However, there were no significant differences in estimated changes in MDA-LDL (p = .235) and LDL-C (p = .323) levels between the two groups. Furthermore, the researchers found no significant correlation between febuxostat doses and the estimated changes in MDA-LDL level (p = .626), LDL-C level (p = .896), or MDA-LDL/LDL-C ratio (p = .747).
These findings suggest a potential beneficial effect of febuxostat in reducing the MDA-LDL/LDL-C ratio, indicating a potential decrease in oxidative stress and atherosclerosis in asymptomatic hyperuricemic patients with carotid atherosclerosis. However, further research is needed to confirm these results and gain a deeper understanding of the clinical antioxidant effects of febuxostat.
Link to the article: https://onlinelibrary.wiley.com/doi/10.1002/clc.24014
References Teragawa, H., Tanaka, A., Fujii, Y., Yoshida, H., Ueda, T., Nomura, S., Kadokami, T., Koide, H., Saito, M., Sano, H., Bando, Y. K., Murohara, T., Node, K., & for the PRIZE Study Investigators. (2023). Effect of febuxostat on the level of malondialdehyde‐modified low‐density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study. Clinical Cardiology, 46(6), 698–706. https://doi.org/10.1002/clc.24014
